Bayer/Schering AG present R&D pipeline, highlighting Nexavar, Campath and Yaz
At its 2006 "Perspective on Innovation" event at its Leverkusen Communications center, German drug and chemicals group Bayer AG discussed the importance of inspiration, ideas and innovation in ensuring the future prosperity of all areas of its business.
The firm's chairman, Werner Wennig, said that "one of the principal keys to success is research." He went on to say that completion of the recent acquisition of Schering AG (Marketletter September 4) had strengthened the company's pharmaceutical research activities, and added that, "never before has the research-intensive pharmaceuticals business accounted for such a large share of the group's sales." He added that, with a turnover of 9.1 billion euros ($11.61 billion), based on the 2005 figures, Berlin-based Bayer Schering Pharma will become one of Germany's biggest pharmaceutical companies.
Pipeline highlights
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze